



THE
BLADDER CANCER
COMPANY

Photocure ASA – Share option grant

Oslo, Norway, 30 March 2023 - Photocure ASA (the "Company") (OSE: PHO) has granted share options to employees.

A total of 33,900 share options, equal to 0.12% of total shares issued in the Company, were granted at an exercise price at NOK 85.78. The exercise price is equal to the weighted average share price 30 trading days before day of grant with an additional premium of 10% on top of the calculated average price.

All of the options have been granted to employees. The options are granted in accordance with Photocure's long term incentive program.

Erik Dahl
Chief Financial Officer
Tel: +47 450 55 000
Email: ed@photocure.no

About Photocure ASA

Photocure: The Bladder Cancer Company delivers transformative solutions to improve the lives of bladder cancer patients. Our unique technology, making cancer cells glow bright pink, has led to better health outcomes for patients worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange (OSE: PHO). For more information, please visit us at www.photocure.com, www.hexvix.com or www.cysview.com.

All trademarks mentioned in this release are protected by law and are registered trademarks of Photocure ASA.

This information is subject to the disclosure requirements pursuant to the market abuse regulation article 19 and 5-12 of the Norwegian Securities Trading Act.